After 96 weeks, 39% of patients offered a 50-mg dose of efruxifermin showed a clinically meaningful reduction in liver fibrosis, or scarring, without other symptoms of MASH getting worse ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic dysfunction-associated steatohepatitis (MASH) analyses to send its stock up about 100%.

MOSCOW, Feb 14 (Reuters) - Authorities in Russia have detained a U.S. citizen at a Moscow airport on drug smuggling charges, Mash, a Telegram channel which has sources in Russia's security ...

Freight vehicle registrations saw an 8.9 per cent rise, reaching 479 compared to 440 in the same month last year. Light trucks increased by 14.7 per cent to 405, heavy trucks by 4.3 per cent to 48 ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Garrett Camp is a tech-oriented entrepreneur who co-founded Uber Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician (CMT). Garrett ...

Welcome to Your Dream Home: Full Turnkey 3 & 4 Bedroom Packages! Introducing our Grade A, Full Turnkey 3 and 4-Bedroom House and Land Packages, ideal for investors and first home buyers.

Welcome to Coin Tree Close, a boutique land estate in the heart of Inala, offering 11 prime blocks ranging from 360m² to 541m². Each block features a generous 12.5m frontage, providing the ...

A group of child survivors behind a barbed wire fence at the Nazi concentration camp at Auschwitz It was 80 years ago that Soviet troops liberated the Nazi death camp at Auschwitz-Birkenau.

This figure comprises a 38-seat business class cabin, followed by 264 economy seats. Both of these sections have relatively high-density layouts, with the business class flatbeds in a 2-2-2 setup, ...

Shares of Akero ascended by 115% in early Monday trading upon the news. MASH-associated cirrhosis patients “face a poor prognosis,” Catriona Yale, chief development officer at Akero, said on an ...